基于结构设计的强效非MDM2抑制剂的结构设计
Ke Ding1, Yipin Lu, Zaneta Nikolovska-Coleska
1Departments of Internal Medicine and Medicinal Chemistry and Comprehensive Cancer Center, and Life Sciences Institute, University of Michigan, 1500 East Medical Center Drive, Ann Arbor, Michigan 48109, USA.
Journal of the American Chemical Society
|July 21, 2005
概括
研究人员设计了强大的非类小分子抑制剂,以p53-MDM2相互作用为目标. 化合物1d有效地抑制前列腺癌细胞的生长,对正常细胞的毒性最小.
科学领域:
- 药用化学 医学化学
- 化学生物学 化学生物学
- 药物设计 药物设计
背景情况:
- 蛋白与蛋白的p53-MDM2相互作用是癌症治疗的关键目标.
- 开发非类小分子抑制剂用于蛋白质-蛋白质相互作用是具有挑战性的.
研究的目的:
- 报告针对p53-MDM2相互作用的新型非类小分子抑制剂的基于结构的设计.
- 评估这些抑制剂在癌细胞中的功效和选择性.
主要方法:
- 基于结构的药物设计方法.
- 非类小分子的合成和表征.
- 生物化学测试以确定结合亲和力 (Ki).
- 基于细胞的测试,以评估细胞生长抑制和毒性.
主要成果:
- 成功设计了一类非类小分子MDM2抑制剂.
- 最强效的化合物1d的基值为86nM,明显超过自然p53的强度.
- 化合物1d证明了强大的抑制LNCaP前列腺癌细胞生长 (野生类型p53) 与最小的活性对PC-3细胞 (删除的p53).
- 化合物1d对正常的前列腺上皮细胞具有最小的毒性.
结论:
- 基于结构的设计是一种可行的策略,用于开发强效的,细胞透的,非抑制剂,针对具有挑战性的蛋白质-蛋白质相互作用.
- 化合物1d代表了开发针对p53-MDM2-依赖性癌症的新疗法的一个有希望的领头羊.
- 开发的抑制剂提供了一个潜在的治疗途径,具有有利的安全性.
相关概念视频
Drug-Receptor Bonds
Drug-receptor bonds are formed through various chemical forces when drugs interact with target cells. Covalent bonds, strong and irreversible, are exemplified by DNA-alkylating anticancer agents that inhibit cell division. However, such irreversible drug binding lacks selectivity and can modify the DNA of the surrounding healthy cells. Covalent binding often contributes to tissue toxicity, as seen with chloroform and paracetamol metabolites binding to the liver, causing hepatotoxicity.
In...
In...
Adrenergic Agonists: Chemistry and Structure-Activity Relationship
Adrenergic agonists' structure-activity relationship (SAR) determines their selectivity and efficacy. These agonists comprise a phenylethylamine moiety with an aromatic ring and an ethylamine side chain.
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of the aromatic...
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of the aromatic...
Structure-Activity Relationships and Drug Design
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence its...
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence its...
Modified-Release Drug Delivery Systems: Rate-Programmed II
Rate-programmed drug delivery systems release drugs in a controlled manner to maintain therapeutic levels. Three main designs include reservoir, matrix, and hybrid systems.Reservoir systems consist of a drug core enclosed within a membrane that controls drug release. In non-swelling reservoir systems, polymers like ethyl cellulose or polymethacrylates are used. These do not hydrate in aqueous media and control release through membrane thickness, porosity, or insolubility. This type includes...
Modified-Release Drug Delivery Systems: Classification
Modified-release drug delivery systems improve drug efficacy and minimize side effects by controlling the rate and location of drug release. These systems fall into three categories: rate-programmed, stimuli-activated, and site-targeted.Rate-programmed systems release drugs at a predetermined rate, maintaining consistent therapeutic levels and reducing fluctuations that could lead to toxicity or subtherapeutic effects. These systems use polymeric matrices, reservoir-based designs, or osmotic...
Modified-Release Drug Delivery Systems: Rate-Programmed I
Rate-programmed drug delivery systems (DDS) are designed to release drugs at specific, controlled rates to maintain consistent therapeutic levels. These systems are categorized based on their release mechanisms, including dissolution-controlled DDS, diffusion-controlled DDS, and combined dissolution-diffusion-controlled DDS.In dissolution-controlled DDS, the release rate depends on the slow dissolution of the drug itself or the surrounding matrix. Drugs with inherently slow dissolution rates,...


